DBVT appoints Philina Lee to Board and Compensation Committee

Rhea-AI Filing Summary

DBV Technologies appointed Philina Lee, Ph.D., to its Board of Directors effective October 30, 2025, filling the vacancy created by the resignation of Daniel Soland. She will also join the Compensation Committee in his place, with her appointment to be submitted to a shareholder vote at the next annual Ordinary and Extraordinary General Meeting.

Lee brings senior commercial and portfolio leadership experience from Blueprint Medicines, Sanofi, Genzyme and Algeta, and prior board service at Fusion Pharmaceuticals. Under the company’s non-employee director compensation policy, she will receive a fixed annual retainer of €100,000 and €5,000 per year for Compensation Committee service.

8-K Event Classification

3 items: 5.02, 7.01, 9.01

3 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

00-0000000 true 0001613780 false 0001613780 2025-10-30 2025-10-30 0001613780 us-gaap:CommonStockMember 2025-10-30 2025-10-30 0001613780 dei:AdrMember 2025-10-30 2025-10-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

October 30, 2025

Date of Report (Date of earliest event reported)

DBV Technologies S.A.

(Exact name of registrant as specified in its charter)

France		001-36697		Not applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

107 avenue de la République 92320 Châtillon France				Not Applicable
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: +33 1 55 42 78 78

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary shares, nominal value €0.10 per share		n/a		The Nasdaq Stock Market LLC *
American Depositary Shares, each representing five ordinary shares, nominal value €0.10 per share		DBVT		The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the registration of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 30, 2025, Philina Lee was appointed to the Board of Directors (the “Board”) of DBV Technologies S.A. (the “Company”) effective immediately, to fill the vacancy created by the resignation of Daniel Soland. Ms. Lee will also serve as a member of the Compensation Committee, in replacement of Mr. Soland. Ms. Lee’s appointment will be submitted to a shareholder vote at the next convened annual Ordinary and Extraordinary General Meeting of shareholders.

Ms. Lee, Ph.D., age 49, previously served as Chief Commercial Officer of Blueprint Medicines since April 2022. She joined Blueprint Medicines in August 2014 as Senior Director, New Product Strategy and Development and subsequently held multiple commercial roles with responsibility for strategy, operations, patient services, marketing and the precision medicine field team. From January 2021 to April 2022, she served as Senior Vice President, Head of Portfolio Strategy and Program Management. Previously, Dr. Lee held product strategy and marketing roles of increasing responsibility at Algeta, Sanofi and Genzyme. She previously served on the board of Fusion Pharmaceuticals, as a member of both the Nomination and Governance committee and Research and Development committee from 2021 to 2024. Philina earned a B.S. in Biochemistry from the University of Alberta, and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.

There are no arrangements or understandings between Ms. Lee and any other person pursuant to which Ms. Lee was appointed as a director. Ms. Lee does not have any family relationships with any of the Company’s directors or executive officers, and she does not have a direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Ms. Lee will be compensated in accordance with the Company’s non-employee director compensation policy. Ms. Lee will receive a fixed annual retainer of €100,000 per year for her service as a director. Ms. Lee will also receive €5,000 per year for her service as a member of the Compensation Committee.

Item 7.01 Regulation FD Disclosure.

The Company issued a press release on October 30, 2025 announcing the appointment described in Item 5.02 above. The press release making this announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Description
99.1		Press Release dated October 30, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

				DBV Technologies S.A.
Date: October 30, 2025				By:		/s/ Virginie Boucinha
				Name:		Virginie Boucinha
				Title:		Chief Financial Officer

FAQ

What did DBVT announce in this 8-K?

DBV Technologies appointed Philina Lee, Ph.D., to its Board and the Compensation Committee, effective October 30, 2025.

Whom does Philina Lee replace on the DBVT board?

She fills the vacancy created by the resignation of Daniel Soland and replaces him on the Compensation Committee.

Is shareholder approval required for Philina Lee’s appointment at DBVT?

Her appointment will be submitted to a shareholder vote at the next annual Ordinary and Extraordinary General Meeting.

What is the compensation for DBVT’s new director?

Under DBV’s policy, she will receive an annual retainer of €100,000 and €5,000 per year for Compensation Committee service.

What is Philina Lee’s professional background relevant to DBVT?

She served as Chief Commercial Officer at Blueprint Medicines and held senior roles at Sanofi, Genzyme, and Algeta.

Does Philina Lee have related-party ties with DBVT?

The company states there are no arrangements, no family relationships, and no material interests requiring disclosure under Item 404(a).